Novo Nordisk to acquire portfolio company Akero

Summary by AI BETAClose X

International Biotechnology Trust PLC (IBT) noted that Akero Therapeutics, an IBT portfolio company, will be acquired by Novo Nordisk for up to $5.2 billion in cash. Akero shareholders will receive $54.00 per share at closing, plus a Contingent Value Right for $6.00 per share upon full US regulatory approval of efruxifermin (EFX) by June 30, 2031. The offer represents a 19% premium to Akero's 30-day Volume Weighted Average Price and a 42% premium to Akero's closing price on May 19, 2025. As of October 8, Akero represented 2.9% of IBT's Net Asset Value. The updated valuation of IBT's holding in Akero will be included in IBT's NAV as at close of business today, to be reported tomorrow, October 10.

Disclaimer*

UK 100

Latest directors dealings